🌟 Exciting times for our MOTION team! We’re growing and evolving as we enter Year 3 — with new roles, fresh perspectives & shared dedication to advance hepatology and improve patient outcomes. 💪 Here’s to another year of teamwork & innovation! #MOTIONTeam #LiverResearch

🎉 Congrats to Mathias Jachs, MD, PhD on completing his Habilitation at MedUni Vienna — an impressive milestone at such a young age! 👏 His lecture covered liver cirrhosis, CSPH & hepatitis B/D. 💪 We’re proud to have him on our MOTION team! #Hepatology

🩸Next - WP6: Coagulation & Hemostasis Research Our specialists is working to characterize rebalanced hemostasis in #ACLD & #PSVD using advanced diagnostics like #ClotPro & TM-TGA. #Portalhypertension #coagulation #liver #Clinicaltrial

After a long summer break, we continue introducing our work packages of project MOTION. UP next is WP5 introduced and led by @mathiasjachs.bsky.social 🖐️ Developing prognostic #NIT models for #ACLD or #PSVD 📷More info in the video below 📷

🙌We wrapped up an amazing MOTION annual meeting! 🙌 Reflected on 2 years of growth & scientific insights, and set course for the next 2 years. Next step: making our 3 clinical trials – and project MOTION as a whole – an outstanding success! 💫 #MotionProject #TeamScience #ClinicalTrials

👋 After a short break, we continue to introduce our WPs to you👋 Next one is MOTION WP 4 led and introduced by @mattiasmandorfer.bsky.social - Comparing #HVPG responses of our medication within our clinical trials to NSBBS... 🌐More info in the video below 📷🔽

💫This week we are introducing WP4 & WP5 💫 Focused on HVPG response to therapy, NIT-based prognostic models, & clinical outcomes in #ACLD/#PSVD. 🔬 A comprehensive approach to #hepatology research. Led by @mattiasmandorfer.bsky.social & @mathiasjachs.bsky.social 📷More info in the graphic 📷

🎥 Say hi to Work Package 3 of the #MotionProject! WP lead Dr. Georg Semmler gives a quick introduction into how we’re tackling PSVD—from molecular insights to clinical impact. 💡 Watch now & learn more about our mission in hepatology! #WP3 #LiverResearch #PSVD #ScienceInMotion

🧬 WELCOME to WP3, In this WP we're exploring the molecular & prognostic characterization of PSVD using histology, metabolomics & RNA-seq. The key element: the EXPOSURE trial, investigating anticoagulation with Edoxaban in PSVD patients. #MotionProject #PSVD #WP3 #LiverResearch #ClinicalTrials

🌐 Introducing MOTION WorkPackage 2 by @reibergerthomas.bsky.social 🌐 In this particular WP the team is focusing on decompensated cirrhosis.. #liver #PortalHypertension #clinicaltrails #dACLD 🔽 Find out more in the video below 📷🔽

🧠 New paper by @LorenzBalcar shows that #spleenstiffness measurement (SSM) via transient elastography helps non-invasively stratify #portalhypertension in BCR::ABL1⁻ MPN — beyond #liver stiffness. A step forward in risk assessment! 📊👇More info 📊👇 lnkd.in/du8-FjgE

Some of our Motion team members are currently at #EASL2025 in Amsterdam — proudly representing our deep expertise in liver research and innovation. Come say hi if you're around! 👋 #MotionTeam #EASL2025 #LiverResearch #Innovation #ProudToRepresent

#Portalhypertension Fans ⬇️ 🥂🥂 OUR deputy PI @MattiasMandorf1 . received the "EASL Emerging Leader Awards 2025" in Amsterdam yesterday at #EALS2025 We congratulate him from the bottom of our #livers 😉 and are incredibly proud!

🌐 MOTION Work Package 2 🌐 WP2 focuses on decompensated cirrhosis. Heart of the this wp is a clinical trial led by @reibergerthomas.bsky.social investigating the potential beneficial effects of norfloxacin in this patient group. ⬇️⬇️⬇️⬇️ #liver #liverdesease #PortalHypertension #ClinicalTrial

#liver #PortalHypertension #clinicaltrails #cACLD Introducing MOTION WP 1 - Focusing on pathophysiological mechanisms in compensated Patients with liver cirrhosis.... 🌐More info in the video below 🌐 🔽🔽

💬Introducing WP1💬 This WP focuses on the classical & alternative renin-angiotensin system as a disease-driving mechanism in patients with cACLD. The heart of WP1 is a clinical trail to investigate potentially beneficial effects of telmisartan in this patient group.

🌐Fridays with the MOTION Team = science, smiles & serious vibes 😎🧪 Just something else.... :) 🌐 When top-notch research meets good energy, magic happens. Work hard, laugh harder — that’s how we roll. #MOTIONProject #ScienceSquad #FridayFeeling #TeamworkMakesTheDreamWork

🌟 Our MOTION team is growing – so are our achievements! 🌟 While knowledge is undoubtedly necessary in a project, people form the foundation of success... Physicians, PhDstudents, PMs, StudyNurses & DataManagers bring their unique skills & perspectives that make our MOTION project truly special

🥳🥳 Proud to announce that another VLSG member Nikolaus Pfisterer has successfully defended his #PhD at @meduniwien.ac.at 🙌🙌🙌 Congrats and let's celebrate!! 🙌🙌🙌

MEET the MOTION Team! A team of clinical & basic researchers, assembled by @reibergerthomas.bsky.social & @mattiasmandorfer.bsky.social to conduct clinical studies & translational research on PH-driving molecular mechanisms. Those aspiring members are divided in 8 WPs assigned to their expertise.

#PortalHypertension Fans !! #liver 👍 We are thrilled to share that our clinical trial is in full swing! It is divided in 8 work packages and over the upcoming weeks, we’ll introduce each innovative work package, with the dedicated experts, driving this project forward. ⬇️📷More info 📷⬇️

🚀 Behind the abbreviation MOTION is a top-tier clinical research group at MedUni Vienna tackling portal hypertension – the key driver of liver disease morbidity & mortality. 🔬 ⬇️ Follow for more info... ⬇️ #portalhypertension #research #clinicaltrail #liver #blueskyliver